Insulin-like growth factor binding protein-1 is a long-term predictor of heart failure in survivors of a first acute myocardial infarction and population controls

Janszky, Imre; Hallqvist, Johan; Ljung, Rickard; Hammar, Niklas

doi:10.1016/j.ijcard.2008.08.003

Cited by 13 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biggest differences were observed for Insulin-like growth factor-binding protein 1 (30%); Azurocidin, Cystatin-B, and Myeloperoxidase (13%); Monocyte chemotactic protein 1 (11%); and Myeloblastin (10%), all 120 minutes after food intake. Insulin-like growth factor-binding protein 1 has been shown to predict cardiovascular mortality and morbidity in patients with acute myocardial infarction [19,20]. The level of insulin-like growth factor-binding protein has been shown to regulate insulin-like growth factor-I bioactivity, glucose homeostasis, and tissue regeneration, and increases during inflammation [21].…”

Section: Resultsmentioning

confidence: 99%

Effect of food intake on 92 biomarkers for cardiovascular disease

et al. 2017

View full text Add to dashboard Cite

ObjectiveThe present study evaluates the effect of food intake on 92 biomarkers for cardiovascular disease (CVD).MethodsTwenty two healthy subjects (11 male and 11 female aged 25.9±4.2 years) were investigated. A total of 92 biomarkers were measured before a standardized meal as well as 30 and 120 minutes afterwards with the Proseek Multiplex CVD III kit.ResultsThe levels for eight biomarkers decreased significantly (P<0.05) 30 minutes after food intake. The levels for seven biomarkers remained significantly decreased 120 minutes after food intake. Nine biomarker decreased significantly at 120 minutes after food intake. The changes were between 4–30%, most commonly around 5%. Only six biomarkers showed a difference of 10% or more due to food intake. The biggest differences were observed for Insulin-like growth factor-binding protein 1 (30%); Azurocidin, Cystatin-B, and Myeloperoxidase (13%); Monocyte chemotactic protein 1 (11%); and Myeloblastin (10%), all 120 minutes after food intake.ConclusionsThis study shows that food intake affects several different CVD biomarkers, but the effect is predominantly modest. Timing of blood sampling in relation to food intake, therefore, appears not to be a major concern. Further studies are warranted in older healthy subjects and in patients with various cardiac diseases to determine whether the findings are reproducible.

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of food intake on 92 biomarkers for cardiovascular disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Specifically, high circulating concentrations of IGFBP1 have been linked with the development of heart failure in the elderly (50) and with an adverse prognosis after myocardial infarction (51,52). Associated changes in COOH-terminal provasopressin (copeptin) may explain the apparent prognostic importance of IGFBP1 concentrations highlighted in these trials (53); however, further studies of the molecular effects of IGFBP1 in these clinical scenarios are clearly warranted.…”

Section: Discussionmentioning

confidence: 99%

Increasing Circulating IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against Atherosclerosis

et al. 2012

View full text Add to dashboard Cite

Low concentrations of insulin-like growth factor (IGF) binding protein-1 (IGFBP1) are associated with insulin resistance, diabetes, and cardiovascular disease. We investigated whether increasing IGFBP1 levels can prevent the development of these disorders. Metabolic and vascular phenotype were examined in response to human IGFBP1 overexpression in mice with diet-induced obesity, mice heterozygous for deletion of insulin receptors (IR+/−), and ApoE−/− mice. Direct effects of human (h)IGFBP1 on nitric oxide (NO) generation and cellular signaling were studied in isolated vessels and in human endothelial cells. IGFBP1 circulating levels were markedly suppressed in dietary-induced obese mice. Overexpression of hIGFBP1 in obese mice reduced blood pressure, improved insulin sensitivity, and increased insulin-stimulated NO generation. In nonobese IR+/− mice, overexpression of hIGFBP1 reduced blood pressure and improved insulin-stimulated NO generation. hIGFBP1 induced vasodilatation independently of IGF and increased endothelial NO synthase (eNOS) activity in arterial segments ex vivo, while in endothelial cells, hIGFBP1 increased eNOS Ser1177 phosphorylation via phosphatidylinositol 3-kinase signaling. Finally, in ApoE−/− mice, overexpression of hIGFBP1 reduced atherosclerosis. These favorable effects of hIGFBP1 on insulin sensitivity, blood pressure, NO production, and atherosclerosis suggest that increasing IGFBP1 concentration may be a novel approach to prevent cardiovascular disease in the setting of insulin resistance and diabetes.

show abstract

“…Irrespective of diabetes, high IGFBP-1 serum concentrations were correlated with and thus predictive for an increased risk of cardiovascular and coronary heart disease mortality in elderly men ( 26 ). Likewise, in survivors of a previous (first) AMI, higher circulating IGFBP-1 concentrations predicted heart failure as demonstrated by a prospective study ( 27 ) which included male and female subjects between 45 and 70 years of age. Interestingly, higher IGFBP-1 concentrations were informative for mortality in subjects with no history of heart failure after a follow-up of 8 years.…”

Section: Igfbp-1mentioning

confidence: 82%

“…Nevertheless, the authors also concluded that assessment of IGFBP-1 and IGF-I could be used for the identification of adult subjects at an increased risk of fatal IHD as well as for the selection of an appropriate intervention strategy. The reasons underlying the contradictory biomarker information of IGFBP-1 are not directly evident, because the follow-up periods were 9–13 years in one study ( 28 ) and 8 years in the later study ( 27 ). A possible explanation may be deduced from the fact that the study by Janszky et al was restricted to the risk of heart failure but not to all-cause mortality or mortality related to cardiovascular disease.…”

Section: Igfbp-1mentioning

confidence: 99%

Current IGFBP-Related Biomarker Research in Cardiovascular Disease—We Need More Structural and Functional Information in Clinical Studies

2018

View full text Add to dashboard Cite

Cardiovascular diseases are the leading cause of death around the world and the insulin-like growth factor (IGF)-system has multiple functions for the pathological conditions of atherosclerosis. IGF binding proteins (IGFBPs) are widely investigated as biomarkers for pathological disorders, including those of the heart. At the tissue level, IGFBP-1 to -6 decrease bioactivity of IGF-I and -II due to their high affinity IGF-binding sites. By contrast, in the circulation, the IGFBPs increase biological half-life of the IGFs and may therefore be regarded as positive regulators of IGF-effects. The IGFBPs may also exert IGF-independent functions inside or outside the cell. Importantly, the circulating IGFBP-concentrations are regulated by trophic, metabolic, and reproductive hormones. In a multitude of studies of healthy subjects and patients with coronary heart diseases, various significant associations between circulating IGFBP-levels and defined parameters have been reported. However, the complex hormonal and conditional control of IGFBPs may explain the lack of clear associations between IGFBPs and parameters of cardiac failure in broader studies including larger populations. Furthermore, the IGFBPs are subject to posttranslational modifications and proteolytic degradation by proteases, upon which the IGFs are released. In this review, we emphasize that, with the exception of IGFBP-4 and in sharp contrast to the preclinical studies, virtually all clinical studies do not have structural or functional information on their biomarker. The use of analytical systems with no discriminatory potential toward intact vs. fragmented IGFBPs represents a major issue in IGFBP-related biomarker research and an important focus point for the future. Overall, measurements of selected IGFBPs or more complex IGFBP-signatures of the family of IGFBPs have potential to identify pathophysiological alterations in the heart or patients with high cardiovascular risk, particularly if defined cohorts are to be assessed. However, a more thorough understanding of the dynamic IGF-IGFBP system as well as its proteases and protease inhibitors in both normal physiology and in cardiovascular diseases is necessary.

show abstract

Insulin-like growth factor binding protein-1 is a long-term predictor of heart failure in survivors of a first acute myocardial infarction and population controls

Cited by 13 publications

References 22 publications

Effect of food intake on 92 biomarkers for cardiovascular disease

Effect of food intake on 92 biomarkers for cardiovascular disease

Increasing Circulating IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against Atherosclerosis

Current IGFBP-Related Biomarker Research in Cardiovascular Disease—We Need More Structural and Functional Information in Clinical Studies

Contact Info

Product

Resources

About